Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that it has selected Destum Partners to assist in finding a development partner for its psoriasis compound, KM-133. Cellceutix management has carefully evaluated which direction to take in the development of KM-133 and has concluded that this is the best way to create shareholder value...

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis...

Molecular dermatology research and development innovator DermaGenoma, Inc. today announced that the PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) is now available as a CE Marked product under the European In Vitro Diagnostic Directive. CE Marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives...

Mothers who drank milk with a probiotic supplement during and after pregnancy were able to cut the incidence of eczema in their children by almost half, a new study published in the British Journal of Dermatology has shown...